Search results

We want you to be involved in our work - whether you’re commenting on our draft recommendations, taking part in guidance development or attending a committee meeting, your voice is important to us.

Summary of the evidence on insulin degludec/liraglutide (Xultophy) for treating type 2 diabetes to inform local NHS planning and decision-making

Result type

Evidence summary

Published

3 July 2015

This indicator covers the percentage of adults and young people at a GP surgery in an area of high or extremely high HIV prevalence who have not had an HIV test in the last 12 months, who are having a blood test and receive an HIV test at the same time. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM190

Result type

General practice indicators suitable for use outside of QOF

Published

31 July 2019

This indicator covers the percentage of adults and young people newly registered with a GP in an area of high or extremely high HIV prevalence who receive an HIV test within 3 months of registration. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM189

Result type

General practice indicators suitable for use outside of QOF

Published

1 August 2019

We work with the clinical classifications service of NHS England to provide relevant clinical coding information for interventional procedures.

GPs help to bring a primary care perspective to the guidance that we produce.

GPs help to bring a primary care perspective to the guidance that we produce.

Evidence-based recommendations on biomarker tests to help diagnose preterm labour in women with intact membranes. The tests are Actim Partus, PartoSure and the Rapid fetal fibronectin (fFN) 10Q Cassette Kit (at thresholds other than 50 nanograms/millilitre).

Result type

HealthTech guidance

Published

4 July 2018

Evidence-based recommendations on sacubitril valsartan (Entresto) for treating symptomatic chronic heart failure with reduced ejection fraction.

Result type

Technology appraisal guidance

Published

27 April 2016

This indicator covers the percentage of people aged 45 to 84 years who have a recorded cardiovascular disease (CVD) risk assessment score in the preceding 5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

Result type

Network / system level indicators

Published

15 August 2024

All the templates and supporting documents you need to make a technology appraisals submission with NICE.

Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with reduced ejection fraction in adults.

Result type

Technology appraisal guidance

Published

9 March 2022

Evidence-based recommendations on bulevirtide (Hepcludex) for chronic hepatitis D in adults.

Result type

Technology appraisal guidance

Published

7 June 2023

Our forward view highlights the areas we will prioritise in the coming year.

of healthcare professionals, including primary care colleagues, work with NICE to develop our recommendations. From GPs and community...